Clinical Trial Update: Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 clinical trial evaluating a CD19/CD20 dual-targeted cellular therapy in relapsed/refractory B-cell non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Snippet

Sponsor: Beijing GoBroad Hospital | Conditions: B-cell Non-Hodgkin Lymphoma Recurrent B-cell Non-Hodgkin Lymphoma Refractory | EARLY_Phase 1 | Status: RECRUITING